| Literature DB >> 18665189 |
H G Mulholland1, L J Murray, C R Cardwell, M M Cantwell.
Abstract
Long-term consumption of a high glycaemic index (GI) or glycaemic load (GL) diet may lead to chronic hyperinsulinaemia, which is a potential risk factor for cancer. To date, many studies have examined the association between GI, GL and cancer risk, although results have been inconsistent, therefore our objective was to conduct a systematic review of the literature. Medline and Embase were systematically searched using terms for GI, GL and cancer to identify studies published before December 2007. Random effects meta-analyses were performed for endometrial cancer, combining maximally adjusted results that compared risk for those in the highest versus the lowest category of intake. Separate analysis examined risk by body mass index categories. Five studies examining GI and/or GL intake and endometrial cancer risk were identified. Pooled effect estimates for endometrial cancer showed an increased risk for high GL consumers (RR 1.20; 95% CI: 1.06-1.37), further elevated in obese women (RR 1.54; 95% CI: 1.18-2.03). No significant associations were observed for GI. Only two studies examined ovarian cancer and therefore no meta-analysis was performed, but results indicate positive associations for GL also. A high GL, but not a high GI, diet is positively associated with the risk of endometrial cancer, particularly among obese women.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18665189 PMCID: PMC2527795 DOI: 10.1038/sj.bjc.6604496
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1A flow diagram of study selection for GI/GL and endometrial and ovarian cancer risk.
Characteristics of studies included in systematic review of dietary glycaemic index, glycaemic load and risk of endometrial and ovarian cancer
|
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||
| | Prospective cohort (6.4 years) | 710 | 288 428 | Self-reported/interviewed FFQ and 24-h recall | 9/9 | 56 (53–58) | 117 (94–144) | ✓ | ✓ | ✓ | # | # | # | ✓ | ✓ | # | # | ✓ | ||
| | Prospective cohort (15.6 years) | 608 | 66 651 | Self-reported 67-item FFQ, 96-item FFQ | 9/9 | 80 (74–86) | 181 (155–210) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | # | # | ✓ | # | |||
| | Prospective cohort (16.4 years) | 426 | 34 391 | Self-reported 86-item FFQ | 9/9 | 73 (67–77) | 148 (125–169) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| | Prospective cohort (−) | 415 | 23 335 | Self-reported 126-item FFQ | 9/9 | 85 (81–89) | 170 (147–193) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
| | Hospital-based case–control | 410 | 753 | Interviewed 37-item FFQ | 6/9 | 82 | 143 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
|
| ||||||||||||||||||||
| | Prospective cohort (16.4 years) | 264 | 48 776 | Self-reported 86-item FFQ | 9/9 | 77 (63–92) | 148 (125–169) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| | Hospital-based case–control | 1031 | 2411 | Interviewed 78-item FFQ | 6/9 | 74 (70–78) | 185 (147–234) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
FFQ=Food Frequency Questionnaire; GI=glycaemic index; GL=glycaemic load; IQ=Inter-quartile.
Adjusted confounders: age; BMI=body mass index; Energy=energy intake; Hormon.=hormone replacement therapy/oral contraceptive use; Reprod.=reproductive factors, e.g., parity, age at first birth; Menstr.=menstrual history, e.g., age at menarche or menopause, menopausal status; Smoking; PA=physical activity; Education; Alcohol intake; Fibre=Fibre intake; Diabetes=History of diabetes.#Indicates potential confounders that were tested but not included in the final model.
Total follow-up length 304 558 women-years. 1Values from Swiss centre, 2Values from Italian centre.
Figure 2Meta-analysis of GI and endometrial cancer risk.
Figure 3Meta-analysis of GL and endometrial cancer risk.
Figure 4Meta-analysis of GL and endometrial cancer risk by BMI categories: normal weight (BMI < 25 kg/m2), overweight (BMI ⩾25 and <30 kg/m2) and obese (BMI ⩾30 kg/m2).